Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Chief Operating Officer | February 27, 2025 | March 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phathom Pharmaceuticals, Inc.
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 312,590 |
Reported balance
After 2025-02-27 transaction · row 1
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 79,200 · Balance 312,590 F1: Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.76 · Expires 2035-02-26 | Direct | 55,000 |
Reported balance
After 2025-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-27 · Grant · Acquired 55,000 · Balance 55,000 F2: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 3,578.93 |
Reported balance
Holding disclosure · report date 2025-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,578.93 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 785,700 |
Reported balance
Holding disclosure · report date 2025-02-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 785,700 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2025 Filed Mar 3, 2025 17:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0000950170-25-031034 · ownership.xml · derivative · entry 4 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-02-26 F2 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 17:13 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 79,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-031034 · ownership.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,590 F1 · shares: Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:21 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 7,886 | $6.59 | $51,956.91 |
DisclosureSEC source: 0000950170-25-008353 · ownership.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,390 F1 · shares: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6650. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 1,973 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 16:21 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,118 | $8.00 | $8,944.00 |
DisclosureSEC source: 0000950170-24-139063 · ownership.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,303 F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 14:52 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 10,901 | $11.72 | $127,759.72 |
DisclosureSEC source: 0000950170-24-084186 · ownership.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,421 F1 · kind: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. F2 · balance_after: Includes 1,754 shares acquired in January 2024 and 1 share acquired in July 2024 under the Phathom Pharmaceuticals, Inc. employee stock purchase plan Read SEC document |
| May 31, 2024 Filed May 31, 2024 18:34 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stoock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-067539 · ownership.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,567 F1 · shares: Represents restricted stock units ("RSUs") granted on May 31, 2024. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of December 18, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 20:21 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001209191-24-002020 · doc4.xml · derivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2034-01-17 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 16:54 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054352 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,067 F1 · shares: Represents shares earned with respect to performance stock unit awards granted on July 1, 2020 and January 19, 2023 that contained a performance-vesting requirement that was satisfied on November 1, 2023. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 17:00 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Disposition to issuerStock Option · Derivative | 150,000 | Not disclosed Strike: $39.11 | Not disclosed |
DisclosureSEC source: 0001209191-23-042453 · doc4.xml · derivative · entry 5 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2031-01-27 F1 · price: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 17:00 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | Disposition to issuerStock Option · Derivative | 70,000 | Not disclosed Strike: $32.20 | Not disclosed |
DisclosureSEC source: 0001209191-23-042453 · doc4.xml · derivative · entry 4 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2030-06-30 F1 · price: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 17:00 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 110,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-042453 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,567 F1 · price: On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 11, 2023 Filed Apr 11, 2023 16:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | PurchaseCommon Stock | 10,000 | $8.26 | $82,600.00 |
DisclosureSEC source: 0001209191-23-023989 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,567 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.20 to $8.50. The Reporting Person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 19:35 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001209191-23-004339 · doc4.xml · derivative · entry 4 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-18 F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 19:35 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004339 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,567 F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes 2,596 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 16:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048471 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,971 F1 · shares: Represents restricted stock units ("RSUs") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes 1,093 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2022. Read SEC document |
| May 19, 2022 Filed May 20, 2022 17:19 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031090 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,378 F1 · shares: Represents restricted stock units ("RSUs") granted on May 19, 2022. One third (1/3) of the total number of RSUs granted vest on November 19, 2022, May 19, 2023 and November 19, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| May 16, 2022 Filed May 16, 2022 20:48 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | PurchaseCommon Stock | 20,000 | $8.16 | $163,288.00 |
DisclosureSEC source: 0001209191-22-029453 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 785,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.00 to $8.43. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 18:52 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 97,500 | $0.00 Strike: $15.21 | $0.00 |
DisclosureSEC source: 0001209191-22-004496 · doc4.xml · derivative · entry 4 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2032-01-18 F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 18:52 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004496 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,378 F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. F2 · balance_after: Includes 1,425 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2021 and January 2022 and 453 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan which were inadvertenly omitted from the most recent Form 4. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,089 | $37.86 | $41,230.52 |
DisclosureSEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 5 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 765,700 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.7550 to $38.06. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,400 | $37.09 | $51,921.24 |
DisclosureSEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 4 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 766,789 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.66 to $37.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,968 | $36.15 | $71,150.09 |
DisclosureSEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 3 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 768,189 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.66 to $36.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:31 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 5,753 | $38.59 | $221,994.46 |
DisclosureSEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 2 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 770,157 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 to $38.97. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:31 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 4,290 | $37.85 | $162,359.77 |
DisclosureSEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 775,910 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.15 to $38.12. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 19:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 785 | $37.11 | $29,133.78 |
DisclosureSEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 5 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 780,200 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.04 to $37.24. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 19:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 4,316 | $36.37 | $156,953.93 |
DisclosureSEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 4 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 780,985 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.04 to $37.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 19:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 4,252 | $35.66 | $151,645.45 |
DisclosureSEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 3 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 785,301 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.01 to $36.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 19:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,742 | $38.14 | $66,441.80 |
DisclosureSEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 2 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 789,553 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 to $38.55. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 19:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 3,405 | $37.28 | $126,926.82 |
DisclosureSEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 791,295 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $37.73. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 20:20 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,070 | $46.23 | $95,694.65 |
DisclosureSEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 7 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 794,700 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.81 to $46.57. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 20:20 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,600 | $45.17 | $72,275.52 |
DisclosureSEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 6 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 796,770 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.76 to $45.55. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 20:20 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 24 | $46.73 | $1,121.52 |
DisclosureSEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 5 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 798,370 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.66 to $46.56. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 20:20 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 4,833 | $46.16 | $223,079.68 |
DisclosureSEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 4 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 798,394 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $44.88. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 20:20 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 600 | $44.60 | $26,757.00 |
DisclosureSEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 3 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 803,227 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.99 to $46.13. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 20:20 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,548 | $46.05 | $71,292.99 |
DisclosureSEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 2 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 803,827 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.96. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 20:20 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 3,825 | $45.77 | $175,068.72 |
DisclosureSEC source: 0001209191-21-017484 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 805,375 Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 16:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 6,384 | $41.16 | $262,782.04 |
DisclosureSEC source: 0001209191-21-007185 · doc4.xml · nonDerivative · entry 3 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 809,200 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.87 to $41.56. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 16:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,700 | $40.51 | $109,373.49 |
DisclosureSEC source: 0001209191-21-007185 · doc4.xml · nonDerivative · entry 2 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 815,584 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.86 to $40.85. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:05 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 5,416 | $38.09 | $206,285.15 |
DisclosureSEC source: 0001209191-21-007185 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 818,284 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.58 to $38.87. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 16:32 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $39.11 | $0.00 |
DisclosureSEC source: 0001209191-21-006106 · doc4.xml · derivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 18:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 2,995 | $45.57 | $136,482.15 |
DisclosureSEC source: 0001209191-20-061593 · doc4.xml · nonDerivative · entry 4 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 838,200 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.42 to $45.73. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 18:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 4,307 | $45.05 | $194,030.35 |
DisclosureSEC source: 0001209191-20-061593 · doc4.xml · nonDerivative · entry 3 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 841,195 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $45.41. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 18:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,828 | $44.83 | $81,949.24 |
DisclosureSEC source: 0001209191-20-061593 · doc4.xml · nonDerivative · entry 2 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 845,502 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.65 to $44.97. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 18:01 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 5,370 | $43.99 | $236,226.30 |
DisclosureSEC source: 0001209191-20-061593 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 847,330 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.50 to $44.50. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 18:40 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 14,500 | $36.83 | $534,026.30 |
DisclosureSEC source: 0001209191-20-056768 · doc4.xml · nonDerivative · entry 3 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 852,700 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:48 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001209191-20-040415 · doc4.xml · derivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on July 1, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document |
| June 25, 2020 Filed Nov 3, 2020 18:40 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GiftCommon Stock | 867,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056768 · doc4.xml · nonDerivative · entry 2 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 867,200 Read SEC document |
| June 25, 2020 Filed Nov 3, 2020 18:40 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | GiftCommon Stock | 867,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056768 · doc4.xml · nonDerivative · entry 1 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 05, 2020 Filed Jan 5, 2021 19:17 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 1,854 | $33.77 | $62,608.47 |
DisclosureSEC source: 0001209191-21-001622 · doc4.xml · nonDerivative · entry 4 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 823,700 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.5 to $34.01. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2020 Filed Jan 5, 2021 19:17 UTC | Phathom Pharmaceuticals, Inc. PHAT · Entity 5177 | SaleCommon Stock | 100 | $34.57 | $3,457.00 |
DisclosureSEC source: 0001209191-21-001622 · doc4.xml · nonDerivative · entry 3 Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 825,554 F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.